Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00831896 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00831896 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT00831896, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study is a multicenter, open-label, dose escalation, phase 1 study of TAK 701 in adult patients with advanced nonhematologic malignancies. This study will be the first to administer TAK 701 to humans. The primary purpose of this study is to determine the safety profile, tolerability, and pharmacokinetics profile of TAK-701.
Interventions
- BIOLOGICAL TAK-701
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00831896
The ClinicalTrials.gov registry entry for NCT00831896 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-701 is the first listed.
NCT00831896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00831896 about?
NCT00831896 is a clinical study titled "Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies". This study is a multicenter, open-label, dose escalation, phase 1 study of TAK 701 in adult patients with advanced nonhematologic malignancies. This study will be the first to administer TAK 701 to humans. The primary purpose of this study is to determine the safety profile, tolerability, and pharma...
What is the current status of trial NCT00831896?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2009-03. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00831896?
The interventions under investigation include: TAK-701 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00831896?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.